Neoadjuvant treatment of breast cancer--Clinical and research perspective.

作者: Sibylle Loibl , Carsten Denkert , Gunter von Minckwitz

DOI: 10.1016/J.BREAST.2015.07.018

关键词:

摘要: Abstract Neoadjuvant therapy is very often an adequate alternative to adjuvant therapy. This review summarizing the recent advances made in area of neoadjuvant breast cancer. The focus will lie on recently published clinical trials but not further highlight surgical, imaging and radiooncological issues related Recent findings Within last 1–1.5 years it has been discussed if treatment can be used as faster way get access new therapies, based data HER2+ cancer suggesting a higher pCR rate when dual anti-HER2 was used. Nevertheless this does necessarily translate always into better survival. In TNBC carboplatin could identified asset for patients, especially patients with gBRCA mutations. However, mature long term are still missing. approach ideal identify biomarkers which predict response or resistance given treatment. Tumour infiltrating lymphocytes PIK3CA mutations amongst most promising markers. Summary should considered all HER2-positive triple negative Clinical setting currently investigating approaches.

参考文章(61)
Peter Kern, Anne Kalisch, Hans-Christian Kolberg, Rainer Kimmig, Friederich Otterbach, Gunter von Minckwitz, William M. Sikov, Dirk Pott, Christian Kurbacher, Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of feasibility and rates of pathologic complete response. Chemotherapy. ,vol. 59, pp. 387- 394 ,(2013) , 10.1159/000362756
Michael Untch, Christian Jackisch, Andreas Schneeweiß, Bettina Conrad, Bahriye Aktas, Carsten Denkert, Holger Eidtmann, Hermann Wiebringhaus, Sherko Kümmel, Jörn Hilfrich, Mathias Warm, Stefan Paepke, Marianne Just, Claus Hanusch, John Hackmann, Jens-Uwe Blohmer, Michael Clemens, Serban Dan Costa, Bernd Gerber, Valentina Nekljudova, Sibylle Loibl, Gunter von Minckwitz, Abstract S2-07: A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69 Cancer Research. ,vol. 75, ,(2015) , 10.1158/1538-7445.SABCS14-S2-07
Mothaffar F Rimawi, Polly A Niravath, Tao Wang, Brent Rexer, Andres Forero, Antonio C Wolff, Rita Nanda, Anna M Storniolo, Ian Krop, Matthew P Goetz, Julie R Nangia, Sao Jiralerspong, Anne C Pavlick, Carolina Gutierrez, Rachel Schiff, Susan G Hilsenbeck, C Kent Osborne, Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer Cancer Research. ,vol. 75, ,(2015) , 10.1158/1538-7445.SABCS14-S6-02
Martine J Piccart-Gebhart, Andrew Peter Holmes, Jose Baselga, Evandro De Azambuja, Amylou C Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Sergio Santillana, Kathleen I Pritchard, Antonio C Wolff, Christian Jackisch, Istvan Lang, Michael Untch, Ian E Smith, Frances Boyle, Binghe Xu, Henry Leonidas Gomez, Richard D Gelber, Edith A Perez, None, First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). Journal of Clinical Oncology. ,vol. 32, pp. 502- 502 ,(2014) , 10.1200/JCO.2014.32.18_SUPPL.LBA4
S. Kümmel, J. Holtschmidt, S. Loibl, Surgical treatment of primary breast cancer in the neoadjuvant setting British Journal of Surgery. ,vol. 101, pp. 912- 924 ,(2014) , 10.1002/BJS.9545
Fausto Petrelli, Andrea Coinu, Karen Borgonovo, Mary Cabiddu, Mara Ghilardi, Veronica Lonati, Sandro Barni, The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis Breast Cancer Research and Treatment. ,vol. 144, pp. 223- 232 ,(2014) , 10.1007/S10549-014-2876-Z
A Contreras, S Herrera, T Wang, I Mayer, A Forero, R Nanda, M Goetz, JC Chang, AC Pavlick, SAW Fuqua, C Gutierrez, SG Hilsenbeck, MM Li, CK Osborne, R Schiff, MF Rimawi, Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients Cancer Research. ,vol. 73, ,(2013) , 10.1158/0008-5472.SABCS13-PD1-2
Michael Untch, Sibylle Loibl, Joachim Bischoff, Holger Eidtmann, Manfred Kaufmann, Jens-Uwe Blohmer, Jörn Hilfrich, Dirk Strumberg, Peter A Fasching, Rolf Kreienberg, Hans Tesch, Claus Hanusch, Bernd Gerber, Mahdi Rezai, Christian Jackisch, Jens Huober, Thorsten Kühn, Valentina Nekljudova, Gunter von Minckwitz, Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial Lancet Oncology. ,vol. 13, pp. 135- 144 ,(2012) , 10.1016/S1470-2045(11)70397-7
E Alba, J Albanell, J de la Haba, A Barnadas, L Calvo, P Sánchez-Rovira, M Ramos, F Rojo, O Burgués, E Carrasco, R Caballero, I Porras, A Tibau, M C Cámara, A Lluch, Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. British Journal of Cancer. ,vol. 110, pp. 1139- 1147 ,(2014) , 10.1038/BJC.2013.831